Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Arcus Biosciences, Inc. (RCUS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Quarterly results
Docs: "Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update • Presented data from the ongoing ARC-7 Phase 2 trial in non-small cell lung cancer at American Society of Clinical Oncology ; Fc-silent anti-TIGIT monoclonal antibody domvanalimab continued to demonstrate clinically meaningful improvements over anti-PD-1 monotherapy across all measures evaluated, including progression-free survival, overall response rate, and duration of response • Initiated the dose-expansion phase of the Phase 1b ARC-20 study of AB521, a potential best-in-class HIF-2a inhibitor, in clear-cell renal cell carcinoma patients at a dose of 100 mg daily; pharmacokinetic, pharmacodynamic and safety data, along with any preliminary signs of anti-tumor activity from the d..."
05/09/2023 8-K Quarterly results
Docs: "Arcus Biosciences Reports First Quarter 2023 Financial Results and Provides a Pipeline Update • Four Phase 3 and two Phase 2 trials are now enrolling to evaluate domvanalimab-based combinations in lung and gastrointestinal cancers. • The third dose-escalation cohort of ARC-20 for AB521, a potential best-in-class HIF-2a inhibitor, is enrolling; the dose-expansion stage of ARC-20 and a Phase 2 combination study in clear-cell renal cell carcinoma patients are expected to begin in the third quarter. • Three new drug candidates are expected to advance into the clinic in 2023 and early 2024. • With $1.0 billion in cash, cash equivalents and marketable securities and funding into 2026, Arcus is well-positioned to advance its pipeline. HAYWARD, Calif. – – May 9, 2023 – ..."
08/03/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
02/23/2022 8-K Quarterly results
Docs: "Arcus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update • Presentations of randomized data for domvanalimab and etrumadenant in 1L PD-L1 high non-small cell lung cancer and quemliclustat in pancreatic cancer are planned for 2H:22 • Initial pharmacokinetic /pharmacodynamic data for AB521, Arcus’s HIF-2a inhibitor, in healthy volunteers confirm its potential to have an improved clinical profile compared to the approved HIF-2a inhibitor; data to be presented at a conference this March • First patient dosed in PACIFIC-8, a registrational, Phase 3 study evaluating domvanalimab plus durvalumab in unresectable, Stage 3 NSCLC with AstraZeneca; this represents the second Phase 3 study to be initiated for domvanalimab in NSCLC ..."
11/08/2021 8-K Quarterly results
Docs: "Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab  Both domvanalimab-containing arms demonstrated differentiated clinical activity compared to that of zimberelimab alone in a second interim analysis of ARC-7, our randomized Phase 2 study in first-line metastatic non-small cell lung cancer  Gilead Sciences has initiated its opt-in review process for our anti-TIGIT program o If the option is exercised and closed, Arcus would receive a $275 million opt-in payment, and the parties would share equally R&D expenses related to the anti-TIGIT program o A decision is expected prior to the end of 2021  Updated data from ARC-8, a Phase 1study of quemliclustat, our small molecule anti-CD73 inhibitor for pancreat..."
08/05/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
02/24/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Arcus Biosciences Announces Third Quarter 2020 Financial Results and Corporate Updates"
08/06/2020 8-K Quarterly results
05/05/2020 8-K Quarterly results
Docs: "Arcus Biosciences Announces First Quarter 2020 Financial Results and Corporate Updates"
03/05/2020 8-K Quarterly results
11/05/2019 8-K Quarterly results
08/06/2019 8-K Quarterly results
05/02/2019 8-K Quarterly results
Docs: "Arcus Biosciences Announces First Quarter 2019 Financial Results and Recent Corporate Updates &#45"
03/05/2019 8-K Quarterly results
Docs: "Arcus Biosciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Updates &#45"
11/08/2018 8-K Quarterly results
Docs: "Arcus Biosciences Announces Third Quarter 2018 Financial Results and Recent Corporate Updates -"
08/06/2018 8-K Quarterly results
Docs: "Arcus Biosciences Announces Second Quarter 2018 Financial Results and Recent Corporate Updates - Initiated the Phase 1/1b program for AB928 combinations; Initial dose-escalation data for all four combinations expected in the first half of 2019 - -"
05/09/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Arcus Biosciences Announces First Quarter 2018 Financial Results and Recent Corporate Updates"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy